National registry for rare skin cancer diagnoses
Part of Cancer, Infections clinical trials.
This trial is a French national database that collects information from people with certain rare skin cancers. It may help researchers better understand these cancers and improve future care, using real-world patient data.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with one of these: Merkel cell carcinoma, advanced basal cell carcinoma needing whole-body treatment, or cutaneous adnexal carcinoma
- Your diagnosis has been confirmed by tissue biopsy (histology)
- Your cancer is at an advanced stage for basal cell skin cancer that needs systemic (whole-body) treatment
- You are willing to participate (not refusing)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CRD3874-SI for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
This study looks at how people with Merkel cell carcinoma take part in clinical trials. It helps researchers understand what helps or makes it hard for patients to join and stay in studies.
This study looks for Merkel cell carcinoma cells in the blood before and after surgery (and/or radiation). It may help researchers understand how these cells change with treatment.
This study uses information from a European registry to learn how real-world treatments work for advanced non-melanoma skin cancers. It may help doctors improve care in the future, especially for people who have had surgery and radiation or who cannot have curative treatments.
This study looks at how insurance covers immunotherapy given before surgery for certain skin cancers. It includes people with Merkel cell, mucosal melanoma, basal cell, or other rare skin cancers who are planning to have surgery.
This study is a German “registry,” meaning it collects information about people with specific bone or soft tissue tumors (including some borderline or hard-to-classify cases). It helps doctors and researchers learn more about these rare conditions to improve future care.
Hear when a new Merkel Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.